Squarepoint
CRNX icon

Squarepoint’s Crinetics Pharmaceuticals CRNX Stock Holding History

Squarepoint’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-42,070
Closed -$1.21M – 4448
2025
Q2 		$1.21M Sell
42,070
-97,422
-70% -$3.01M ﹤0.01% 2500
2025
Q1 		$4.68M Buy
+139,492
New +$5.21M 0.01% 1466
2024
Q4 		– Sell
-34,646
Closed -$1.77M – 5094
2024
Q3 		$1.77M Buy
34,646
+7,642
+28% +$394K ﹤0.01% 2153
2024
Q2 		$1.21M Sell
27,004
-7,179
-21% -$332K ﹤0.01% 2416
2024
Q1 		$1.6M Sell
34,183
-27,935
-45% -$1.09M ﹤0.01% 2247
2023
Q4 		$2.21M Buy
62,118
+31,226
+101% +$958K ﹤0.01% 1932
2023
Q3 		$919K Buy
30,892
+781
+3% +$16.1K ﹤0.01% 2382
2023
Q2 		$543K Buy
+30,111
New +$600K ﹤0.01% 2573
2022
Q1 		– Sell
-12,554
Closed -$357K – 2932
2021
Q4 		$357K Buy
+12,554
New +$309K ﹤0.01% 2355
2021
Q1 		– Sell
-15,406
Closed -$217K – 3192
2020
Q4 		$217K Buy
+15,406
New +$215K ﹤0.01% 2450

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Squarepoint's CRNX Position: Q3 2025 in Review

Squarepoint sold out of Crinetics Pharmaceuticals (CRNX) in Q3 2025, closing a stake of 42,070 shares — an estimated $1.21M sold.

Squarepoint first reported a position in CRNX in Q4 2020 and held it in 10 quarters. The position peaked at $4.68M in Q1 2025. 225 funds tracked by Wall St. Rank hold CRNX as of Q3 2025.

  • Squarepoint reported no remaining Crinetics Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Squarepoint sold 42,070 Crinetics Pharmaceuticals shares in Q3 2025, an estimated $1.21M.
  • Squarepoint first reported a position in Crinetics Pharmaceuticals in Q4 2020 and held it in 10 quarters.
  • Squarepoint's Crinetics Pharmaceuticals position peaked at $4.68M in Q1 2025.
  • 225 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2025.

Based on Squarepoint's 13F filing for Q3 2025, filed 14 Nov 2025.